Jonathan J. Miner, MD, PhD

Assistant Professor of Medicine, Molecular Microbiology, and Pathology and Immunology

Related Links
  • B.A., Russian, cum laude: BYU, Provo, UT (2002)
  • B.S., Zoology, cum laude: BYU, Provo, UT (2002)
  • PhD, Biochemistry: University of Oklahoma, Oklahoma City, OK (2008)
  • MD: University of Oklahoma, Oklahoma City, OK (2010)
  • Internal Medicine Resident: Barnes-Jewish Hospital, St. Louis, MO (2012)
  • Rheumatology Fellow: Barnes-Jewish Hospital, St. Louis, MO (2015)
  • Postdoctoral Fellow: Michael S. Diamond Laboratory, Washington University School of Medicine, St. Louis, MO (2016)
Board Certifications
  • Board Certification in Internal Medicine and Rheumatology
  • 1997 – BYU Presidential Scholar
  • 1997 – Philo T. Farnsworth Governor’s Award (top science student in Utah)
  • 2007 – Award for Writing in the History of Cardiovascular Medicine (Texas Heart Institute)
  • 2008 – Fred and Marie Gray Research Achievement Award (University of Oklahoma)
  • 2011 – Resident of the Month (Barnes-Jewish Hospital)
  • 2013 – Teaching Fellow of the Year (Internal Medicine House Staff)
  • 2015 – Scientist Development Award (Rheumatology Research Foundation)
  • 2016 – Distinguished Fellow Award (American College of Rheumatology)
  • 2018 – Young Physician-Scientist Award (American Society for Clinical Investigation)
  • 2018 – Ann Palmenberg Junior Investigator Award (American Society for Virology)
  • 2019 – Clinical Top 10% Faculty Award (Washington University School of Medicine)


  • Associate Scientific Advisor, Science Translational Medicine (2017-2018)
  • Board of Directors, Saint Louis Rheumatology Association (2017-present)

Research Interests

The Miner laboratory studies the intersection of autoimmunity and antiviral immunity.  This includes studies of rare rheumatic diseases caused by mutations in antiviral genes.

Examples of ongoing work in the Miner laboratory include:

  1. The identification and characterization of novel regulators of innate immune signaling pathways including the cGAS-STING pathway.
  2. Studies to determine how the commensal virome and microbiome can influence rare rheumatic diseases and immunodeficiencies, including STING-associated vasculopathy with onset in infancy (SAVI), retinal vasculopathy with cerebral leukoencephalopathy (RVCL), chronic mucocutaneous candidiasis (CMC), and monogenic systemic lupus erythematosus (SLE).
  3. Viral pathogenesis, studies including collaborations with the Baldridge, Klein, and Diamond laboratories (among others).

The primary goal of this work is to define the fundamental immunological mechanisms related to host-microbe interactions and innate immune signaling pathways.

Some of the Miner laboratory’s discoveries include the identification of novel regulators of cGAS-STING signaling, as well as the unexpected finding that SAVI develops independently of type I interferon receptor signaling. The Miner laboratory also recently discovered that STING gain-of-function mutations block development of innate lymphoid cells and lymph nodes in mice.

Another important area of research in the laboratory is the study of RVCL, a rare genetic disease that causes multiple organ damage and premature death.  Dr. Miner cares for RVCL patients from across the country.  He also leads clinical trials and translational studies, with the goal of finding an effective treatment for RVCL.

Bibliography – Jonathan J. Miner